AP 23451

Drug Profile

AP 23451

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator ARIAD Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bone cancer; Malignant hypercalcaemia

Most Recent Events

  • 18 Nov 2003 Discontinued - Preclinical for Bone cancer in USA (unspecified route)
  • 18 Nov 2003 Discontinued - Preclinical for Malignant hypercalcaemia in USA (unspecified route)
  • 07 Jul 2003 Data presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO-2003) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top